A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors. The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main questions it aims to answer are: * what is an appropriate dose to be given to patients? * are the side effects of treatment manageable? Participants will be evaluated for participation in the study. Patients who are treated will receive an intravenous infusion of NPX267 every three weeks if their disease has not progressed. Patients will be closely monitored by the treating physician.
Checked against the public recordLast updated Jun 27, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- NextPoint Therapeutics, Inc.
- Interventions being studied
- Drug: NPX267
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Normal bone marrow, kidney and liver function * Willing to use highly effective contraceptive measures throughout the trial Exclusion Criteria: * Have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy \> 6 months, or changes in skin pigmentation * Have known or suspected brain metastases, unless they are clinically stable * Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily * History of grade 3 immune-related pneumonitis or colitis
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Johns Hopkins University Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
- Massachusetts General HospitalBoston, Massachusetts
- Albert Einstein Medical College Montefiore Medical CenterNew York, New York
- Sarah Cannon Research Institute Oncology PartnersNashville, Tennessee
- MD Anderson Cancer CenterHouston, Texas
- NEXT Oncology-San AntonioSan Antonio, Texas
- NEXT Oncology-FairfaxFairfax, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 27, 2025. Always confirm current availability with the study team.